Press Releases Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
2.89 ^USD	+0.27%		-11.35%	+22.98%

04-23	Lixte Biotechnology Files Up to $50 Million Mixed Shelf	MT
03-27	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lixte Biotechnology : Investor Presentation - April 2024	04-30	PU
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	03-27	AQ
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	03-21	AQ
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research	02-27	AQ
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	02-26	AQ
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial	01-29	AQ
Lixte Biotechnology : Investor Presentation - November 2023	11-20	PU
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations	11-13	AQ
LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration	16/10/23	AQ
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach	09/10/23	AQ
Lixte Biotechnology : Investor Fact Sheet – October 2023	03/10/23	PU
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer	26/09/23	AQ
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer	20/09/23	AQ
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules	18/07/23	AQ
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy	17/07/23	AQ
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements	23/06/23	AQ
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas	07/06/23	AQ
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023	02/06/23	AQ
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy	30/05/23	AQ
Lixte Biotechnology : 10-Q Filing Q1 2023	10/05/23	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Press Releases

Filters